The selection of a container type for pharmaceutical packaging isn’t merely a physical choice—it directly impacts the chemical, physical, and microbiological stability of the product. A mismatch between the formulation and container can lead to degradation, assay variation, and regulatory non-compliance. This tutorial delves into how various container types affect stability outcomes and what parameters must be considered during packaging development.
Role of Container Type in Stability Testing
During ICH stability studies, the container becomes the product’s primary defense against environmental stressors such as heat, humidity, light, and oxygen. Regulatory guidelines require that stability data be generated using the actual market-intended container closure system (CCS). Thus, choosing the wrong container can invalidate the stability results altogether.
Refer to ICH guidelines for container-specific stability recommendations.
Common Container Types in Pharmaceutical Packaging
Let’s look at the common container types and their respective pros and cons in the context of stability:
- Glass Vials (Type I): Highly inert and impermeable, ideal for injectables and sensitive APIs.
- Plastic Bottles (HDPE, PET): Common for oral liquids and solids, but more permeable to moisture and gases.
- Blister Packs (PVC, PVDC, Aclar): Great for unit-dose formats, require evaluation for delamination and seal integrity.
- Ampoules: Hermetically sealed glass, excellent for light and oxygen-sensitive solutions.
- Sachets and
Key Factors Affected by Container Type
The choice of container influences several critical stability outcomes:
- Assay and Degradation: Some plastic containers can adsorb or leach chemicals, altering API levels.
- Moisture Uptake: Non-glass containers may allow water ingress, accelerating hydrolysis.
- Oxygen Permeation: HDPE bottles and some blister films may not provide adequate oxygen barriers.
- Light Protection: Amber glass offers better protection than transparent polymers.
- Migration of Additives: Plasticizers and stabilizers may migrate into the drug product.
These effects must be simulated in forced degradation and long-term studies to assess real-world performance.
Comparative Study Example: Glass vs Plastic for Oral Solutions
In a comparative study of a vitamin C oral solution, batches stored in Type I glass showed less than 1% assay loss at 3 months under 40°C/75% RH. Meanwhile, the same solution in PET bottles degraded by nearly 5%, attributed to oxygen ingress through the polymer. This illustrates how material permeability influences stability—even when both containers meet pharmacopeial standards.
Checklist for Evaluating Container Type During Development
- ✅ Chemical compatibility with formulation (avoid reactivity)
- ✅ Water vapor transmission rate (WVTR)
- ✅ Oxygen transmission rate (OTR)
- ✅ Resistance to light, breakage, and stress
- ✅ Closure system compatibility and sealing integrity
- ✅ Suitability for sterilization (if required)
- ✅ Global regulatory acceptability
These parameters should be evaluated under simulated transport and storage conditions before final selection.
Regulatory Expectations for Container Selection
Regulators like the USFDA and EMA mandate that stability data must reflect the final market presentation. If a different container is used during R&D, bridging studies or justifications are required in the dossier.
- Include extractables and leachables studies (USP , )
- Document justification for container choice
- Provide validation reports for sealing and integrity
These records should appear in CTD Module 3.2.P.7 of the regulatory submission.
How to Conduct Compatibility Testing Based on Container Type
Container compatibility must be tested throughout the product lifecycle. Key test methods include:
- Assay and impurity profile trending over time
- Leachables identification using LC-MS, GC-MS, ICP-MS
- Stress testing at ICH conditions (30°C/65% RH, 40°C/75% RH)
- Photostability testing per ICH Q1B
- Container Closure Integrity Testing (CCI) for sterile products
These studies must use samples stored in the exact packaging system proposed for commercial use.
Case Study: Impact of Closure Incompatibility with Plastic Vials
A company conducted a stability study for a pediatric oral antibiotic in plastic vials with screw caps. After three months at 30°C/75% RH, drug loss and microbial contamination were observed. Investigation revealed incomplete sealing due to torque loss under heat expansion. Switching to an induction-sealed cap resolved the issue and ensured container closure integrity (CCI).
This reinforces the need to validate closures in conjunction with container material and product formulation.
Tips for Selecting the Right Container Type Based on Product Class
- Injectables: Type I glass vial or ampoule + rubber stopper + aluminum seal
- Oral liquids: Amber glass or PET bottle + child-resistant cap
- Solid dose forms: PVC/PVDC blister or HDPE bottle with desiccant
- Topicals: Laminate tubes or high-barrier plastic jars
- Inhalers: Aluminum canister with metered dose valve
Always assess container impact on dosage delivery, not just physical stability.
Internal Documentation Requirements for Container Type Evaluation
Ensure the following documents are included in your packaging development file:
- Material specifications and vendor CoAs
- Summary of compatibility studies
- CCI validation reports
- Visual inspection protocols and sealing SOPs
- Photostability and migration test reports
- Packaging description in the stability protocol
Refer to Pharma SOPs for templates to document packaging qualification steps.
Link Between Container Selection and Product Shelf Life
Suboptimal containers can shorten shelf life by accelerating degradation. For instance, polyethylene containers with high moisture permeability may reduce a hygroscopic API’s shelf life from 24 to 12 months. On the contrary, blister packs with Aclar films or glass containers can extend shelf life by reducing environmental exposure.
Hence, container choice is a shelf-life defining factor—not just a packaging decision.
Conclusion
The container type used in pharmaceutical stability testing can make or break a product’s success. By evaluating chemical compatibility, moisture/oxygen permeability, mechanical protection, and regulatory compliance, pharma professionals can select the right packaging solution that ensures product integrity throughout the shelf life. Always integrate container evaluation into the early stages of formulation development and document findings rigorously.
References:
- ICH Q1A(R2) Stability Testing of New Drug Substances and Products
- ICH Q1B Photostability Testing of New Drug Substances and Products
- USP : Containers – Plastics
- USP : Assessment of Extractables
- FDA Guidance for Industry – Container Closure Systems
- EMA Guideline on Plastic Immediate Packaging Materials